Alfacalcidol increases cancellous bone in low turnover, fatty marrow sites in aged, orchidectomized rats

X.Y. Tian¹, H.Y. Chen¹, R.B. Setterberg¹, M. Li², W.S.S. Jee¹

¹Division of Radiobiology, Department of Radiology, University of Utah School of Medicine, Salt Lake City, UT, USA; ²Osteoporosis Research, Department of Cardiovascular and Metabolic Disease, Pfizer Global Research and Development, Groton, CT, USA

Abstract

The objectives of this study were to determine the responses of cancellous bone in the distal tibial metaphysis (DTM), a low turnover, fatty (yellow) marrow site, to sham-aged, orchidectomy (ORX) and alfacalcidol treatment in sham-aged and ORX rats. Eighteen-month-old male sham and ORX rats were treated with 0.1 and 0.2 µg/kg alfacalcidol 5 days/wk p.o. for 12 weeks, double fluorescent labeled, and the DTM were processed for bone histomorphometry analyses. The current study found the DTM in sham-aged male rats were resistant to age-related and ORX-induced cancellous bone loss and alfacalcidol-induced bone gain, findings that differ from that in the proximal tibial metaphysis (PTM) and lumbar vertebral body (LVB), two high turnover, red marrow bone sites. However, alfacalcidol treatment increased DTM bone mass in ORX rats where bone turnover was elevated by androgen deficiency. These results in concert with the previously positive findings in red marrow bone sites following alfacalcidol treatment suggest that alfacalcidol is more effective in increasing cancellous bone mass in the skeletal sites with higher bone turnover.

Keywords: Alfacalcidol, Orchidectomy, Histomorphometry, Bone Turnover, Bone Balance

Introduction

Previous studies have shown that the cancellous bone in the distal tibial metaphysis (DTM), an adult, low turnover, yellow (fatty) marrow site, behaves differently than high bone turnover, red (hematopoietic) marrow sites such as the proximal tibial metaphysis (PTM) and lumbar vertebral body (LVB), in responding to aging and ovariectomy (OVX) in female rats. The DTM did not have any age-related and OVX-induced cancellous bone loss, a common finding that usually is seen in the PTM and LVB. Interestingly, the DTM did develop immobilization-induced bone loss and responded to parathyroid hormones and prostaglandin-E2 anabolic treatments. However, the responses of the DTM to aging and androgen deficiency induced by orchidectomy (ORX) in male rats remain unknown.

Alfacalcidol has been shown to exert dual anti-catabolic and anabolic properties. It increased cancellous bone mass in red marrow sites with relatively higher bone turnover such as LVB and PTM and prevented age-related cancellous bone loss in the red marrow bone site of aged male rats. In addition, it prevented cancellous bone loss and restored bone mass in OVX rats. Furthermore, alfacalcidol had a better effect in increasing bone mass in the red than in the yellow marrow bone sites in female rats. It is unknown whether the DTM would respond to alfacalcidol treatment in a similar manner as the red marrow bone we have studied.

Thus, the objective of the current study was to investigate the responses of cancellous bone in the DTM of male rats to sham-aged, ORX and alfacalcidol treatment. To achieve this objective we did the following analyses on the DTM of sham-aged and ORX rats following vehicle or alfacalcidol treatment: (1) the effects of aging in male rats from 18 to 21 months; (2) the effects of orchidectomy; (3) the effects of alfacalcidol treatment in sham-aged male rats; (4) the effects of alfacalcidol treatment in ORX rats; and (5) the comparative effects of alfacalcidol treatment in sham-aged and ORX rats.
which were stored at -20°C until assay. The right tibiae were
assessed. Blood samples were centrifuged to obtain the sera,
protected from light, and stored at 4°C. The dosing solutions
the compound in 100% ethanol at a concentration of 0.1 mg/ml,
oral gavage. Alfacalcidol stock solution was made by dissolving
(0.2 Ìg/ml for 0.1 and 0.2 Ìg/ml for 0.1 and
were prepared weekly by diluting the stock solution with cot-
were anesthetized with an intraperitoneal injection of ketamine
were subjected to sham surgeries. The rats received vehicle
in three of the groups of rats and the remaining three groups of
were anesthetized with an intraperitoneal injection of ketamine
and weighed an average of 540g at the beginning of the
The animals were housed at 24°C with a 12:12 h
light/dark cycle and allowed free access to water and were
restricted to 28 grams/day of a commercial diet (Purina
Laboratory Rodent Chow 5001, Purina-Mills, St. Louis,
MO) containing 0.95% calcium, 0.67% phosphorus and 4.5
IU/g of vitamin D3. The experiments were conducted according
to Pfizer’s Animal Care and Use Committee approved
protocols, and the rats were maintained in accordance with
the ILAR (Institute of Laboratory Animal Research) Guide
for the Care and Use of Laboratory Animals.
Seventy rats were randomly divided into 7 groups with 10 per
group. One group of rats was killed at the beginning of the
experiment to serve as baseline controls, and the rest of rats
were anesthetized with an intraperitoneal injection of ketamine
hydrochloride and xylazine at doses of 50 and 10mg/kg body
weight, respectively. Bilateral orchidectomies were performed
at the conclusion of 12 weeks of treatment with alfacalcidol, the rats
were fasted 16 hours prior to necropsy. On the day of necropsy,
whole blood samples were collected by cardiac puncture imme-
diately after euthanasia by CO₂ asphyxiation for biochemical
assessments. Blood samples were centrifuged to obtain the sera,
which were stored at -20°C until assay. The right tibiae were
harvested and prepared for bone histomorphometry analysis.

Table 1. Serum Biochemistry.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Vehicle</th>
<th>0.1</th>
<th>0.2</th>
<th>Vehicle</th>
<th>0.1</th>
<th>0.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum calcium (mg/dl)</td>
<td>12.44±0.47</td>
<td>12.08±0.34</td>
<td>12.72±0.55</td>
<td>13.24±0.48*</td>
<td>12.13±0.33</td>
<td>12.69±0.59*</td>
<td>14.17±0.43*</td>
</tr>
<tr>
<td>Serum inorganic phosphorus (mg/dl)</td>
<td>7.43±0.88</td>
<td>6.56±0.71*</td>
<td>7.94±0.98*</td>
<td>8.28±1.03*</td>
<td>6.87±0.74</td>
<td>7.18±0.92</td>
<td>9.27±0.81**</td>
</tr>
</tbody>
</table>

Mean ± SD; (% change from Baseline; or/and % change from Sham-aged vehicle; or/and % change from ORX-vehicle). *p<0.05 vs. Baseline; **p<0.05 vs. Sham-aged vehicle; ***p<0.05 vs. ORX-vehicle. The baseline and sham data were published previously11.

Materials and methods

Animals and materials

The experimental animals were male Sprague-Dawley rats (Harlan, Indianapolis, IN) that were 18-months of age and weighed an average of 540g at the beginning of the study. The animals were housed at 24°C with a 12:12 h light/dark cycle and allowed free access to water and were
restricted to 28 grams/day of a commercial diet (Purina Laboratory Rodent Chow 5001, Purina-Mills, St. Louis,
MO) containing 0.95% calcium, 0.67% phosphorus and 4.5
IU/g of vitamin D3. The experiments were conducted according
to Pfizer’s Animal Care and Use Committee approved
protocols, and the rats were maintained in accordance with
the ILAR (Institute of Laboratory Animal Research) Guide
for the Care and Use of Laboratory Animals.
Seventy rats were randomly divided into 7 groups with 10 per
group. One group of rats was killed at the beginning of the
experiment to serve as baseline controls, and the rest of rats
were anesthetized with an intraperitoneal injection of ketamine
hydrochloride and xylazine at doses of 50 and 10mg/kg body
weight, respectively. Bilateral orchidectomies were performed
at the conclusion of 12 weeks of treatment with alfacalcidol, the rats
were fasted 16 hours prior to necropsy. On the day of necropsy,
whole blood samples were collected by cardiac puncture imme-
diately after euthanasia by CO₂ asphyxiation for biochemical
assessments. Blood samples were centrifuged to obtain the sera,
which were stored at -20°C until assay. The right tibiae were
harvested and prepared for bone histomorphometry analysis.

Bone histomorphometry

The right tibiae were stained en bloc with Villanueva Bone
Stain (Arizona Histology & Histomorphometry Center,
Phoenix, AZ, USA), dehydrated in graded concentrations of
alcohol, defatted in acetone, and embedded in methyl
methacrylate monomer (Fisher Scientific, Fairlawn, NJ,
USA). Sagittal sections of distal tibiae (DTM) were cut at a
230 µm thickness using a Low Speed Diamond Saw (Isomet,
Buehler, Lake Bluff, IL, USA), and then hand ground to a
thickness of 20 µm for histomorphometric analyses15. All
bone measurements were performed using a semi-automatic
Image Analysis System (OsteoMeasure, OsteoMetrics Inc.
Decatur, GA). Cancellous bone measurements were performed
in the area between the former epiphyseal-metaphyseal
junction to 3 mm proximal to the junction.
Measurement parameters of cancellous bone included total
tissue area (T.Ar), trabecular bone area (B.Ar), trabecular bone
perimeter (B.Pm), numbers of nodes (N#), cortical bone to free
end (CTF), node to free end (NTF), free end to free end (FTF),
node to node (NTN), cortical bone to node (CTN), single-
single perimeter (sL.Pm) and double-labeled perimeter (dL.Pm),
interlabel width (Ir.L.Wi), ostoid perimeter (O.Pm), eroded perimeter
(Er.Pm). These indices were used to calculate percent trabecular
bone area (%B.Ar), trabecular width (B.Wi), trabecular number ( Tb.N), trabecular separation (Tb.Sp), numbers of free
ends (F#: CTF+NTF+2xFTF); the ratio of nodes number/free
ends number (N/F) and density of connectivity variables based
on B.Ar and T.Ar, the mineralized perimeter (%L.Pm), mineral-
aposition rate (MAR), percent osteoid perimeter (%O.Pm),
percent eroded perimeter (%Er.Pm) and bone formation rate
per unit of bone area, tissue area and bone surface (BFR/B.Ar,
BFR/T.Ar, BFR/BS)16–19, and the estimated index of tissue level
bone balance (%L.Pm/%Er.Pm)20. The index of tissue level

X.Y. Tian et al.: Effects of alfacalcidol in orchidectomized rats
bone balance was estimated by the ratio of labeled and eroded perimeters (%L.Pm/%Er.Pm). Lastly, the atypical bone formation previously described as bone "boutons" or "bone buds" were observed and quantitated. Tables 1-4 list the calculated differences in responses in alfacalcidol-treated DTM of sham-aged and ORX rats comparing baseline, sham-aged, and ORX controls. Additionally, the same dose of alfacalcidol-treated ORX and sham-aged rats were compared.

Statistical analysis

Data were presented as mean ± SD for each group. Statistics were calculated by an Ultimate Integrated Data Analysis and Presentation System (StatView 5.0.1, SAS Institute Inc. Cary, NC, USA). Across-group comparisons were made with a parametric analysis of variance (ANOVA), followed by Fisher’s protected least significant difference test (PLSD). Differences were considered statistically significant at $p<0.05$ on a two-tailed test. In addition, all groups were analyzed with two-way factorial ANOVA (SPSS, Chicago, IL, USA), where the two factors were alfacalcidol and orchidectomy.

Results

Body weight and serum calcium and phosphorus

The mean body weights of all groups remained constant throughout the study (data not shown).

The serum calcium levels did not differ between the baseline and sham-aged vehicle controls, but the 0.1 µg alfacalcidol/kg-treated sham-aged rats significantly increased by 5% versus sham-aged vehicle control and the 0.2 µg/kg-treated sham-aged rats significantly increased by 6% and 10% over the baseline and sham-aged vehicle controls. The serum calcium levels in ORX-vehicle controls did not differ from baseline and sham-aged vehicle controls; however, the 0.1 µg alfacalcidol/kg dose significantly increased calcium levels by 5% compared to both sham-aged vehicle and ORX-vehicle controls while the 0.2 µg/kg dose increased calcium levels by 14, 17% and 17% in terminal ORX’d treated rats compared to baseline, sham-aged

Table 2. Selective Static Trabecular Bone Histomorphometric Parameters of Distal Tibial Metaphysis.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>Sham-Aged 0.1</th>
<th>ORX - 0.1</th>
<th>Baseline</th>
<th>Sham-Aged 0.1</th>
<th>ORX - 0.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trabecular bone area (%B.Ar, %)</td>
<td>22.49±2.72</td>
<td>25.73±7.22</td>
<td>27.52±5.01</td>
<td>22.49±2.72</td>
<td>25.73±7.22</td>
<td>27.52±5.01</td>
</tr>
<tr>
<td>Trabecular number (Tb.N, #)</td>
<td>2.03±0.25</td>
<td>2.35±0.43</td>
<td>2.01±0.25</td>
<td>2.03±0.25</td>
<td>2.35±0.43</td>
<td>2.01±0.25</td>
</tr>
<tr>
<td>Trabecular separation (Tb.Sp, µm)</td>
<td>388.71±55.79</td>
<td>396.78±54.63</td>
<td>372.49±58.69</td>
<td>388.71±55.79</td>
<td>396.78±54.63</td>
<td>372.49±58.69</td>
</tr>
<tr>
<td>Node to node/total area (NTN/T.Ar, #/mm²)</td>
<td>1.88±0.59</td>
<td>1.68±0.60</td>
<td>2.13±0.79</td>
<td>1.88±0.59</td>
<td>1.68±0.60</td>
<td>2.13±0.79</td>
</tr>
<tr>
<td>Ratio of nodes number/Free ends number (N/F)</td>
<td>1.06±0.61</td>
<td>0.88±0.30</td>
<td>1.01±0.49</td>
<td>1.06±0.61</td>
<td>0.88±0.30</td>
<td>1.01±0.49</td>
</tr>
</tbody>
</table>

Mean ± SD; (% change from Baseline; and/or % change from Sham-aged vehicle; and/or % change from ORX-vehicle; and/or % change from same dose of Sham + Alfacalcidol)

$p<0.05$ vs. Baseline; $p<0.05$ vs. Sham-aged vehicle; $p<0.05$ vs. ORX-vehicle; $p<0.05$ ORX+Alfacalcidol vs. same dose of Sham+Alfacalcidol.

Table 3. Occurrence of Bouton Surface in Alfacalcidol- treated Sham-aged and ORX Rats.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>B.B Frequency (#/An)</th>
<th>B.B.N (#)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>1/10</td>
<td>1.00</td>
</tr>
<tr>
<td>Sham-vehicle</td>
<td>4/10</td>
<td>1.00±0.00</td>
</tr>
<tr>
<td>Sham - 0.1</td>
<td>7/10</td>
<td>1.4±1.38</td>
</tr>
<tr>
<td>Sham - 0.2</td>
<td>10/10</td>
<td>3.2±0.23</td>
</tr>
<tr>
<td>ORX-vehicle</td>
<td>1/10</td>
<td>1.00</td>
</tr>
<tr>
<td>ORX - 0.1</td>
<td>6/10</td>
<td>1.6±1.82</td>
</tr>
<tr>
<td>ORX - 0.2</td>
<td>7/7</td>
<td>3.7±1.29</td>
</tr>
</tbody>
</table>
and ORX-vehicle controls (Table 1).

Serum phosphorus levels significantly dropped 12% in sham-aged vehicle rats while the 0.1 and 0.2 µg alfacalcidol-treated sham-aged animals had significant increases of 21% and 26% versus sham-aged vehicle controls. In contrast, significant increased serum phosphorous levels were limited to the 0.2 µg/kg alfacalcidol-treated ORX rats to 25% and 41% compared to beginning and sham-aged vehicle rats and a significant elevation of 35% from ORX-vehicle rats (Table 1).

**Effects of aging in sham-aged vehicle rats**

Cancellous bone area remained constant while there were significant decreases in node to node population (NTN/T.Ar, -45%) and a non-significant reduction in ratio of node to free end (N/F, -24%; \( p = 0.277 \)) compared to baseline control (Table 2). Four out of 10 sham-aged DTM had one bone bouton site per slide (Table 3).

Histomorphometrically, there was a near significant increase in bone formation-based bone turnover (BFR/B.Ar, 59%, \( p = 0.071 \) with significant increases in index of bone resorption (%Er.Pm, 73%) and surfaced-based bone formation rate (BFR/BS, 70%) indicating a tendency for an index of negative bone balance (-16%) compared to baseline controls (Table 4).

**Effects of androgen deficiency induced by orchidectomy**

Cancellous bone mass, micro-architecture and bone bouton production did not differ from baseline and sham-aged vehicle controls (Tables 2 and 3), even though there were significant increases in bone turnover (BFR/B.Ar, 107%), bone resorption (%Er.Pm, 46%) and bone formation parameters (%L.Pm, 78%; MAR, 13%; BFR/BS, 93%), leading to non-significant increase in index of positive tissue level (17%) compared to sham-aged vehicle controls (Table 4). One out of 10 ORX DTM had one bone bouton site per slide (Table 3).

**Effects of 0.1 µg alfacalcidol/kg in sham-aged rats**

Cancellous bone mass and micro-architecture were unchanged from baseline control but select micro-architectural parameters like trabecular number (Tb.Wi, 18%) and node to node population (NTN/T.Ar, 63%) were increased significantly compared to sham-aged vehicle control rats (Table 2). Bone bouton production was higher in alfacalcidol-treated rats (7 out of 10 versus one and 4 out of 10 from baseline and sham-aged vehicle controls) (Table 3).

Histomorphometrically, there were significant decreases in bone turnover (BFR/B.Ar, -63%), bone resorption (%Er.Pm, -70%) with a similar magnitude of indices of bone formation (%L.Pm, -63% and BFR/BS, -66%) contributing to a non-significant estimate of an increase in index of positive tissue level (%L.Pm/%Er.Pm, 40%) versus sham-aged vehicle controls (Table 4).

**Effects of 0.2 µg alfacalcidol/kg in sham-aged rats**

Cancellous bone mass and micro-architecture were non-significantly increased from baseline and sham-aged vehicle controls; however, trabecular number (Tb.N, 27%), trabecular separation (Tb.Sp, -26%) and node to node population

---

**Table 4.** Selective Trabecular Bone Histomorphometric Parameters of Distal Tibial Metaphysis.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Vehicle</th>
<th>0.1</th>
<th>0.2</th>
<th>Vehicle</th>
<th>0.1</th>
<th>0.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labeled perimeter</td>
<td>5.38±2.41</td>
<td>8.93±3.98</td>
<td>3.31±1.38*</td>
<td>5.03±2.01*</td>
<td>15.87±6.92*</td>
<td>3.97±2.12*</td>
<td>8.50±4.58*</td>
</tr>
<tr>
<td>(L.Pm, %)</td>
<td>(66)</td>
<td>(-38; -63)</td>
<td>(-46; -44)</td>
<td>(-26; -56; -75; 20)</td>
<td>(-25; -56; -77; 31)</td>
<td>(58; -5; -46; 69)</td>
<td></td>
</tr>
<tr>
<td>Mineral apposition rate</td>
<td>0.56±0.11</td>
<td>0.55±0.07</td>
<td>0.53±0.13</td>
<td>0.53±0.12</td>
<td>0.62±0.05*</td>
<td>0.56±0.10</td>
<td>0.62±0.14</td>
</tr>
<tr>
<td>(MAR, µm/day)</td>
<td>(-1)</td>
<td>(-5; -3)</td>
<td>(-4; -4)</td>
<td>(13; 13)</td>
<td>(13; 0; 17)</td>
<td>(13; 0; 17)</td>
<td></td>
</tr>
<tr>
<td>Bone formation rate</td>
<td>2.99±1.43</td>
<td>5.09±2.64*</td>
<td>1.71±0.69*</td>
<td>2.79±1.58*</td>
<td>9.84±4.44*</td>
<td>2.24±1.33*</td>
<td>5.51±3.63</td>
</tr>
<tr>
<td>(BFR/BS, µm/µm²/day100)</td>
<td>(70)</td>
<td>(-43; -66)</td>
<td>(-43; -45)</td>
<td>(-25; -56; -77; 31)</td>
<td>(-25; -56; -77; 31)</td>
<td>(84; 8; -44; 97)</td>
<td></td>
</tr>
<tr>
<td>Bone formation rate</td>
<td>16.99±8.89</td>
<td>27.05±13.95</td>
<td>10.02±4.78*</td>
<td>16.08±9.60*</td>
<td>55.91±22.59*</td>
<td>11.37±6.48*</td>
<td>23.22±10.68*</td>
</tr>
<tr>
<td>(BFR/B.Ar, %/year)</td>
<td>(59)</td>
<td>(-41; -63)</td>
<td>(-41; -41)</td>
<td>(-33; -58; -80; 13)</td>
<td>(-33; -58; -80; 13)</td>
<td>(37; -14; -58; 44)</td>
<td></td>
</tr>
<tr>
<td>Percent Eroded perimeter</td>
<td>1.51±0.78</td>
<td>2.61±0.73*</td>
<td>0.79±0.29*</td>
<td>0.93±0.37*</td>
<td>3.81±1.15*</td>
<td>0.85±0.48*</td>
<td>1.03±0.46*</td>
</tr>
<tr>
<td>(%Er.Pm, %)</td>
<td>(73)</td>
<td>(-48; -70)</td>
<td>(-48; -70)</td>
<td>(-44; -77; -78; 7)</td>
<td>(-44; -77; -78; 7)</td>
<td>(-32; -61; -73; 10)</td>
<td></td>
</tr>
<tr>
<td>Ratio of labeled perimeter/eroded perimeter</td>
<td>4.30±2.82</td>
<td>3.60±1.86 (-16)</td>
<td>5.04±3.42 (17; 40)</td>
<td>6.55±4.96 (53; 82)</td>
<td>4.23±1.90 (-2; 17)</td>
<td>6.47±4.31 (51; 80; 53; 28)</td>
<td>11.55±9.53**</td>
</tr>
<tr>
<td>(%L.Pm/%Er.Pm)</td>
<td>(#)</td>
<td>(17; 40)</td>
<td>(17; 40)</td>
<td>(51; 80; 53; 28)</td>
<td>(51; 80; 53; 28)</td>
<td>(169; 220; 173; 76)</td>
<td></td>
</tr>
</tbody>
</table>

Mean ± SD; (% change from Baseline; and/or % change from Sham-aged vehicle; and/or % change from ORX-vehicle; and/or % change from same dose of Sham + Alfacalcidol)

\[ p < 0.05 \text{ vs. Baseline}; \]
\[ p < 0.05 \text{ vs. Sham-aged vehicle}; \]
\[ p < 0.05 \text{ vs. ORX-vehicle}; \]
\[ p < 0.05 \text{ ORX + Alfacalcidol vs. same dose of Sham + Alfacalcidol}. \]
(NTN/T.Ar, 107%) differed significantly from sham-aged vehicle controls (Table 2). Bone bouton production occurred in all animals at 3.2±2.2 sites per slide (Table 3).

Histomorphometrically, there were significant decreases in bone turnover (BFR/B.Ar, -41%), bone resorption (%Er.Pm, -64%), and bone formation parameters (%L.Pm, -44%; BFR/BS, -45%); but marked, non-significant, increased indication of positive tissue bone balance (%L.Pm/%Er.Pm, 82%, p=0.277) versus sham-aged vehicle controls (Table 4).

**Effects of 0.1 µg alfacalcidol/kg in ORX rats**

There were significant increases in cancellous bone mass (%B.Ar, 22%) and select micro-architectural parameters (trabecular number, 13%; trabecular separation, -16%) compared to baseline controls. Additionally, there were significantly more trabecular bone mass (%B.Ar, 25%), number (Tb.N, 23%), ratio of node to free end (N/F, 97%), and less separation (Tb.Sp, -27%) versus sham-aged vehicle controls (Table 2). Six out of ten ORX DTM showed 3.7±2.9 bone boutons per slide (Table 3).

Compared to baseline controls, this treatment significantly increased cancellous bone mass (%B.Ar, 44%) and improved select micro-architectures in trabecular number (Tb.Wi, 17%), trabecular separation (Tb.Sp, -23%) and ratio of node to free end (N/F, 59%, p=0.071) (Table 2). All 7 out of 7 treated ORX DTM showed 3.7±2.9 bone boutons per slide (Table 3).

Compared to terminal sham-aged vehicle and ORX-vehicle control rats, significant histomorphometrical findings were restricted to depressed bone resorption (%Er.Pm, -61% and -73%) and increased index of positive tissue bone balance (%L.Pm/%Er.Pm, 220% and 173%). In addition, bone turnover was significantly lower (BFR/B.Ar, -58%) versus ORX controls (Table 4).

Factorial ANOVA showed the interaction of ORX and 0.2 µg alfacalcidol/kg had significant influence on changes in trabecular width, ratio of nodes to free ends, bone resorption and bone turnover (Table 6), but no interaction on bone bouton production (data not shown).

**Effects of 0.2 µg alfacalcidol/kg in ORX rats**

Compared to baseline controls, this treatment significantly increased cancellous bone mass (%B.Ar, 44%) and improved select micro-architectures in trabecular number (Tb.Wi, 17%), trabecular separation (Tb.Sp, -23%) and ratio of node to free end (N/F, 97%), and less separation (Tb.Sp, -27%) versus sham-aged vehicle controls (Table 2). Six out of ten ORX DTM showed 3.7±2.9 bone boutons per slide (Table 3).

Compared to terminal sham-aged vehicle and ORX-vehicle control rats, significant histomorphometrical findings were restricted to depressed bone resorption (%Er.Pm, -61% and -73%) and increased index of positive tissue bone balance (%L.Pm/%Er.Pm, 220% and 173%). In addition, bone turnover was significantly lower (BFR/B.Ar, -58%) versus ORX controls (Table 4).

Factorial ANOVA showed the interaction of ORX and 0.2 µg alfacalcidol/kg had significant influence on changes in trabecular width, ratio of nodes to free ends, bone resorption and bone turnover (Table 6), but no interaction on bone bouton production (data not shown).

**Differences in responses to 0.1 µg alfacalcidol/kg between ORX and sham-aged rats**

Significant differences were limited to increased cancellous bone mass by 18% and ratio of node to free end by 80% (Table 2). No difference was observed in bone bouton production (Table 3). There were non-significant differences in increases of select histomorphometric indices in bone turnover (BFR/B.Ar, 13%), bone resorption (%Er.Pm, 7%), bone formation (BFR/BS, 31%) and index of positive tissue bone balance (%L.Pm/%Er.Pm, 28%) compared to sham-aged rats treated with the same 0.1 µg alfacalcidol dose (Table 4).
Differences in responses to 0.2 μg alfalcacidol/kg treatment between ORX and sham-aged rats

There was a non-significant increase in cancellous bone mass (26%, \(p=0.112\)), while significant differences were limited to increased trabecular thickness (Tb.Wi, 24%) and ratio of node to free end (N/F, 67%) (Table 2). No differences were detected in bone bouton production (Table 3). Significant increases in histomorphometric parameters were restricted to percent labeled perimeter (69%), although BFR/BS was nearly significant (97%, \(p=0.051\)). Again, increases of other select indices of histomorphometric parameters were non-significantly different from the sham-aged; but at a higher level in the 0.2 μg dose treated ORX rats where: bone turnover (BFR/B.Ar, 44%), bone resorption (%Er.Pm, 10%) and index of positive tissue bone balance (76%) increased compared to sham-aged rats treated with the same 0.2 μg dose (Table 4).

Discussion

This study was designed to investigate the responses of the cancellous bone in the distal tibial metaphysis (DTM), a low turnover, fatty (yellow) marrow site, to aging, orchidectomy and alfalcacidol treatment in aged male rats. The data yielded the following new findings: (1) age-related changes in the DTM were restricted to the loss in trabecular connectivity (reduced node to node population) in contrast to losses in both cancellous bone mass and bone architecture in the proximal tibial metaphysis and the lumbar vertebral body (high turnover, red marrow sites); (2) orchidectomy did not induce cancellous bone loss or architecture in the DTM but exhibited significantly increased bone turnover with accompanying bone balance in equilibrium (the magnitude of bone formation and resorption is equal to the magnitude of bone formation); (3) alfalcacidol-treatment dose-dependently increased serum calcium and phosphorus in sham-aged and ORX rats; (4) alfalcacidol treatment in sham-aged rats dose-dependently prevented age-related reduction in trabecular connectivity (reduced node to node population), decreased cancellous bone turnover, increased bone bouton production, but did not cause any significant bone gain; (5) alfalcacidol treatment in ORX rats significantly increased cancellous bone mass as well as improved micro-architecture. This effect was accompanied with increased bone bouton production, dose-responsively reduced bone turnover, decreased bone resorption more than bone formation and at the 0.2 μg/kg dose maintained bone formation resulting in bone gain; and (6) alfalcacidol induced bone boutons on cancellous bone of DTM in both sham and ORX rats, a phenomenon that was previously reported only in high turnover, red marrow sites in adult female and aged male rats.

Contrary to the aged-related loss of cancellous bone mass and poorer micro-architecture seen in the cancellous bone of the proximal tibial metaphysis and lumbar vertebral body in aged male rats (21 months vs. 18 months of age), the age-related change in DTM from the same age animals was limited to a reduction in node to node population. However, it had in common to the other red marrow sites, that the DTM showed an age-related increase in bone turnover but differed with no change in bone balance status with bone resorption and formation in equilibrium. Our findings indicate that, unlike in the skeletal sites with relatively high turnover red marrow where testosterone depletion induces cancellous bone osteopenia, testosterone deficiency induced by ORX does not cause bone loss in the DTM. Orchidectomy did markedly increase bone turnover in the DTM, which suggests increased bone turnover alone does not induce cancellous bone loss but it is the imbalance from more bone resorption than formation leading to a negative tissue bone balance in red marrow skeletal sites. In contrast, in the DTM, bone balance was in equilibrium and bone mass

<table>
<thead>
<tr>
<th>Variables</th>
<th>Alfalcacidol</th>
<th>Two-way ANOVA Results (p value)</th>
<th>ORX</th>
<th>Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>%B.Ar (%)</td>
<td>0.001</td>
<td></td>
<td>NS (0.166)</td>
<td>NS (0.097)</td>
</tr>
<tr>
<td>Tb.Wi (µm)</td>
<td>NS (0.232)</td>
<td></td>
<td>NS (0.316)</td>
<td>0.031</td>
</tr>
<tr>
<td>Tb.N (#)</td>
<td>&lt;0.001</td>
<td></td>
<td>NS (0.419)</td>
<td>NS (0.561)</td>
</tr>
<tr>
<td>Tb.Sp (µm)</td>
<td>0.001</td>
<td></td>
<td>NS (0.143)</td>
<td>NS (0.907)</td>
</tr>
<tr>
<td>NTN/T.Ar (#/mm²)</td>
<td>&lt;0.001</td>
<td></td>
<td>0.025</td>
<td>NS (0.717)</td>
</tr>
<tr>
<td>N/F</td>
<td>0.001</td>
<td></td>
<td>NS (0.078)</td>
<td>0.021</td>
</tr>
<tr>
<td>%O.Pm (%)</td>
<td>NS (0.328)</td>
<td></td>
<td>0.013</td>
<td>NS (0.822)</td>
</tr>
<tr>
<td>%L.Pm (%)</td>
<td>0.001</td>
<td></td>
<td>0.002</td>
<td>NS (0.278)</td>
</tr>
<tr>
<td>%Er.Pm (%)</td>
<td>&lt;0.001</td>
<td></td>
<td>0.015</td>
<td>0.035</td>
</tr>
<tr>
<td>MAR (µm/d)</td>
<td>NS (0.735)</td>
<td></td>
<td>0.018</td>
<td>NS (0.761)</td>
</tr>
<tr>
<td>BFR/B.Ar (%/yr)</td>
<td>&lt;0.001</td>
<td></td>
<td>0.001</td>
<td>0.042</td>
</tr>
<tr>
<td>BFR/BS (µm³/µm²/dx100)</td>
<td>0.004</td>
<td></td>
<td>0.001</td>
<td>NS (0.349)</td>
</tr>
<tr>
<td>%L.Pm/%Er.Pm</td>
<td>0.004</td>
<td></td>
<td>NS (0.102)</td>
<td>NS (0.119)</td>
</tr>
</tbody>
</table>

Table 6. Two-way ANOVA Analysis 0.2 μg Alfalcacidol/kg-treated Distal Tibial Metaphysis of Orchidectomized Rats.
remained unchanged; the same condition also occurred in ovariectomized rats.

In both alfalcaldol-treated sham-aged and ORX rats, the bone mass and micro-architectural changes occurred as a result from a combination of depressed bone resorption and formation, in which the depression in bone resorption was greater than the depression in bone formation or decreased resorption without any effect on bone formation, resulting in a positive bone balance and gain. These findings are consistent with previous findings in relatively young rats. In alfalcaldol treated DTM of sham rats, the preventive effect in age-related impairment in cancellous bone connectivity was likely due to the decrease in bone turnover and increase in bone bouton production. In contrast, in the alfalcaldol treated ORX rats, the magnitude of the suppressed bone resorption exceeded that of bone formation, resulting in significant increases in positive bone balance and gain. Apparently, the histomorphometric profile of alfalcaldol-treated DTM in ORX rats was in the mode of a classical anabolic bone drug defined by Riggs and Parfitt - a drug that requires both an increase in bone remodeling and formation phase greater in magnitude than the resorption phase. The 0.2 μg/kg alfalcaldol-treated ORX rats differed from the sham rats receiving the same treatment with higher bone turnover, maintaining bone formation and bone resorption leading to marked increased positive bone balance and bone gain (Tables 2 and 4). Bone formation parameters in the 0.2 μg/kg alfalcaldol-treated ORX rats trended toward significant increases (%L.Pm, +58%, p=0.064; BFR/BS, +84%, p=0.064) compared to baseline and not different from sham-aged vehicle controls, indicating that the treatment did not increase, but at least maintained the overall bone formation in the sham-aged vehicle control level. The combination of maintained bone formation and decreased bone resorption produced a significant increase in positive bone balance between bone formation and resorption resulting in a net bone gain and improved architecture. In addition, the alfalcaldol-treated DTM in ORX rats induced similar increases in bone gain seen in alfalcaldol-treated red marrow LVB sites in aged male rats.

It is unclear how orchidectomy enhanced the positive effect of alfalcaldol in the DTM. One explanation is the response to the stimulation of bone turnover by ORX, which creates a more favorable environment (more BMU creations) for stimulating osteoblastogenesis. The significant interaction between alfalcaldol treatment and ORX in bone turnover and bone resorption as demonstrated by the factorial 2-way ANOVA analysis supports this hypothesis. Orchidectomy-stimulated bone turnover may be accompanied by increased angiogenesis associated with increased osteogenic cells from pericytes outer lining of bone remodeling compartments and circulating osteoblast lineage cells as well as a relatively better nutrient supply; exposure to higher local concentration of alfalcaldol and higher local concentration of bone resorption-derived cytokines and growth factors that are believed to be beneficial in activating osteoblasts to form bone from osteoblast lineage cells and bone lining cells. Consistently, significant interactions were found between alfalcaldol and orchidectomy in increasing bone formation bone area-based (BFR/B.Ar, bone formation-based bone turnover) as assessed by the factorial 2-way ANOVA analysis.

Another finding in the study is the first report of the occurrence of alfalcaldol-induced atypical pattern of bone formation, bone boutons, in cancellous bone of the yellow marrow DTM in sham and ORX rats. Erben et al. first reported bone bouton production in red marrow, bone sites in adult rats receiving pharmacological doses of calcitriol. Subsequently, it was found in the alfalcaldol-treated cancellous bone in PTM and LV of aged male and adult female rats, but not in relatively younger rats. In addition, Liu et al. previously reported a strong positive correlation between the amount of bone boutons and increased connectivity that may influence the maintenance and increase in connectivity with alfalcaldol treatment in the current study.

Based on bone boutons' micro-anatomical features, they are a result of the accumulation of focal packets of bone formation on bone surfaces stimulated by alfalcaldol treatment mainly by mimimodeling, where bone formation occurs on smooth cement lines (i.e., quiescent bone surfaces) without prior osteoclastic bone resorption. Mimimodeling occurs in tibial and vertebral cancellous bone in aging rats as well as in transiliac biopsy specimens from patient who underwent total hip arthroplasty and parathyroid hormone treatment. This focal formed bone at the mimimodeling sites in human specimens are similar to some of the bone boutons observed in the rats treated with alfalcaldol. It is not known how the bone boutons evolved. Unknown changes in the microenvironment, duration of treatment, etc. may play a role in the initiation of bone boutons. Since there were similar incidences of bone bouton formation in both sham and ORX rats, it indicated that ORX, did not play a role in initiation of bone bouton formation.

In the current study, we could not separate the direct and indirect effects of alfalcaldol because of the increase in serum calcium induced by alfalcaldol stimulation of calcium absorption. High calcium stimulates bone formation and inhibits resorption in vivo. It is well established to decrease bone turnover in vivo. Thus, the decrease in bone resorption and maintenance of bone formation may be partially due to the high serum calcium.

In summary, the current study showed that the cancellous bone in the DTM, a low turnover, yellow marrow bone site responded to aging, orchidectomy and alfalcaldol treatment differently than that in PTM and LV, two high turnover, red marrow bone sites. In another words, cancellous bone in the DTM of aged male rats was insensitive to age-related and androgen-induced bone loss or alfalcaldol treatment. However, it responded to alfalcaldol treatment positively when its bone turnover was elevated by androgen deficiency. These results in concert with the previously positive findings in red marrow bone sites following alfalcaldol treatment suggest that alfalcaldol is more effective in increasing cancellous bone mass in the skeletal sites with higher bone turnover.
References


27. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y. Effects of a synthetic vitamin D ana-